Alnylam Pharmaceuticals (ALNY) & Rosetta Genomics (ROSG) Critical Survey

Alnylam Pharmaceuticals (NASDAQ: ROSG) and Rosetta Genomics (NASDAQ:ROSG) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, institutional ownership and risk.

Volatility and Risk

Alnylam Pharmaceuticals has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Rosetta Genomics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Alnylam Pharmaceuticals and Rosetta Genomics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals 2 2 16 0 2.70
Rosetta Genomics 0 1 0 0 2.00

Alnylam Pharmaceuticals presently has a consensus price target of $143.95, suggesting a potential upside of 27.85%. Rosetta Genomics has a consensus price target of $0.02, suggesting a potential downside of 95.35%. Given Alnylam Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Alnylam Pharmaceuticals is more favorable than Rosetta Genomics.

Profitability

This table compares Alnylam Pharmaceuticals and Rosetta Genomics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals -533.52% -38.09% -33.43%
Rosetta Genomics N/A N/A N/A

Institutional and Insider Ownership

93.4% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.8% of Rosetta Genomics shares are owned by institutional investors. 3.7% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Alnylam Pharmaceuticals and Rosetta Genomics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alnylam Pharmaceuticals $89.91 million 126.06 -$490.87 million ($5.42) -20.77
Rosetta Genomics $9.23 million 0.28 -$16.23 million N/A N/A

Rosetta Genomics has lower revenue, but higher earnings than Alnylam Pharmaceuticals.

Summary

Alnylam Pharmaceuticals beats Rosetta Genomics on 8 of the 12 factors compared between the two stocks.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

About Rosetta Genomics

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply